Search

Jeanette E. Chapman

Examiner (ID: 16208, Phone: (571)272-6841 , Office: P/3638 )

Most Active Art Unit
3635
Art Unit(s)
3635, 2407, 3633, 3638, 3765, 3764, 3711, 3408, 3741, 3625, 2773
Total Applications
2706
Issued Applications
2056
Pending Applications
100
Abandoned Applications
562

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19903138 [patent_doc_number] => 12280122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Muscle targeting complexes and uses thereof for treating myotonic dystrophy [patent_app_type] => utility [patent_app_number] => 18/799447 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 39 [patent_no_of_words] => 35283 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18799447 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/799447
Muscle targeting complexes and uses thereof for treating myotonic dystrophy Aug 8, 2024 Issued
Array ( [id] => 19456794 [patent_doc_number] => 12097263 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Muscle targeting complexes and uses thereof for treating myotonic dystrophy [patent_app_type] => utility [patent_app_number] => 18/416981 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 39 [patent_no_of_words] => 40179 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416981 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/416981
Muscle targeting complexes and uses thereof for treating myotonic dystrophy Jan 18, 2024 Issued
Array ( [id] => 19081960 [patent_doc_number] => 20240108761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID [patent_app_type] => utility [patent_app_number] => 18/504029 [patent_app_country] => US [patent_app_date] => 2023-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504029 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/504029
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID Nov 6, 2023 Abandoned
Array ( [id] => 17850505 [patent_doc_number] => 20220280546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 17/736148 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736148 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/736148
Exon skipping oligomer conjugates for muscular dystrophy May 3, 2022 Issued
Array ( [id] => 17980344 [patent_doc_number] => 20220346380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => RNAi Insecticide Materials and Methods [patent_app_type] => utility [patent_app_number] => 17/571193 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571193 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/571193
RNAi insecticide materials and methods Jan 6, 2022 Issued
Array ( [id] => 19700058 [patent_doc_number] => 12194057 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => NXTAR-derived oligonucleotides and uses thereof [patent_app_type] => utility [patent_app_number] => 17/554274 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 130 [patent_no_of_words] => 24851 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554274 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/554274
NXTAR-derived oligonucleotides and uses thereof Dec 16, 2021 Issued
Array ( [id] => 17913532 [patent_doc_number] => 20220315927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => MODULATORS OF YAP1 EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/527953 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17527953 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/527953
MODULATORS OF YAP1 EXPRESSION Nov 15, 2021 Abandoned
Array ( [id] => 17913527 [patent_doc_number] => 20220315922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => Methods and Compositions for Selecting siRNA of Improved Functionality [patent_app_type] => utility [patent_app_number] => 17/520530 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17520530 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/520530
Methods and Compositions for Selecting siRNA of Improved Functionality Nov 4, 2021 Abandoned
Array ( [id] => 17867050 [patent_doc_number] => 20220289785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 17/387495 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387495 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/387495
Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides Jul 27, 2021 Issued
Array ( [id] => 19564945 [patent_doc_number] => 12139707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Stabilized CRISPR complexes [patent_app_type] => utility [patent_app_number] => 17/384417 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 72 [patent_no_of_words] => 65780 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384417 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/384417
Stabilized CRISPR complexes Jul 22, 2021 Issued
Array ( [id] => 17563468 [patent_doc_number] => 20220127617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/380756 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380756 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/380756
TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS Jul 19, 2021 Abandoned
Array ( [id] => 17593491 [patent_doc_number] => 20220143064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => TAU ANTISENSE OLIGOMERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/367242 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367242 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/367242
TAU ANTISENSE OLIGOMERS AND USES THEREOF Jul 1, 2021 Abandoned
Array ( [id] => 17627589 [patent_doc_number] => 20220162604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => ANTISENSE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/364618 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17364618 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/364618
ANTISENSE NUCLEIC ACIDS Jun 29, 2021 Abandoned
Array ( [id] => 17168786 [patent_doc_number] => 20210322456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 17/352716 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25514 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352716 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/352716
BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES Jun 20, 2021 Abandoned
Array ( [id] => 17357105 [patent_doc_number] => 20220017901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 17/345624 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345624 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/345624
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY Jun 10, 2021 Abandoned
Array ( [id] => 17112103 [patent_doc_number] => 20210292700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => METHODS AND SYSTEMS FOR INTRACELLULAR DELIVERY [patent_app_type] => utility [patent_app_number] => 17/339757 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339757 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/339757
METHODS AND SYSTEMS FOR INTRACELLULAR DELIVERY Jun 3, 2021 Pending
Array ( [id] => 17755576 [patent_doc_number] => 11395855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Exon skipping oligomer conjugates for muscular dystrophy [patent_app_type] => utility [patent_app_number] => 17/245735 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 36 [patent_no_of_words] => 33630 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245735 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/245735
Exon skipping oligomer conjugates for muscular dystrophy Apr 29, 2021 Issued
Array ( [id] => 17334573 [patent_doc_number] => 20220000904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => ANTIVIRAL AGENTS FOR TREATMENT OF CORONAVIRUSES [patent_app_type] => utility [patent_app_number] => 17/244272 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244272 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/244272
Antiviral agents for treatment of coronaviruses Apr 28, 2021 Issued
Array ( [id] => 20201738 [patent_doc_number] => 12404507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases [patent_app_type] => utility [patent_app_number] => 17/238612 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 19 [patent_no_of_words] => 24460 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238612 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/238612
Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases Apr 22, 2021 Issued
Array ( [id] => 19551070 [patent_doc_number] => 12134769 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => MicroRNA-198 as a tumor suppressor in ovarian cancer [patent_app_type] => utility [patent_app_number] => 17/236851 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 80 [patent_no_of_words] => 28181 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236851 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/236851
MicroRNA-198 as a tumor suppressor in ovarian cancer Apr 20, 2021 Issued
Menu